JP2022513089A5 - - Google Patents

Info

Publication number
JP2022513089A5
JP2022513089A5 JP2021527849A JP2021527849A JP2022513089A5 JP 2022513089 A5 JP2022513089 A5 JP 2022513089A5 JP 2021527849 A JP2021527849 A JP 2021527849A JP 2021527849 A JP2021527849 A JP 2021527849A JP 2022513089 A5 JP2022513089 A5 JP 2022513089A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical composition
composition according
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021527849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513089A (ja
JP7576799B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/000065 external-priority patent/WO2020106303A1/en
Publication of JP2022513089A publication Critical patent/JP2022513089A/ja
Publication of JP2022513089A5 publication Critical patent/JP2022513089A5/ja
Application granted granted Critical
Publication of JP7576799B2 publication Critical patent/JP7576799B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021527849A 2018-11-20 2019-11-20 皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物 Active JP7576799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769879P 2018-11-20 2018-11-20
US62/769,879 2018-11-20
PCT/US2019/000065 WO2020106303A1 (en) 2018-11-20 2019-11-20 Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers

Publications (3)

Publication Number Publication Date
JP2022513089A JP2022513089A (ja) 2022-02-07
JP2022513089A5 true JP2022513089A5 (cg-RX-API-DMAC7.html) 2023-09-11
JP7576799B2 JP7576799B2 (ja) 2024-11-01

Family

ID=70773565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527849A Active JP7576799B2 (ja) 2018-11-20 2019-11-20 皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物

Country Status (8)

Country Link
US (2) US20220087989A1 (cg-RX-API-DMAC7.html)
EP (2) EP3883553B1 (cg-RX-API-DMAC7.html)
JP (1) JP7576799B2 (cg-RX-API-DMAC7.html)
CN (2) CN113660931B (cg-RX-API-DMAC7.html)
AU (1) AU2019383310B2 (cg-RX-API-DMAC7.html)
CA (1) CA3120351A1 (cg-RX-API-DMAC7.html)
MA (1) MA55143A (cg-RX-API-DMAC7.html)
WO (1) WO2020106303A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
CN117157065A (zh) 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
AU2022398467A1 (en) * 2021-11-23 2024-06-27 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
EP4493169A4 (en) * 2022-03-17 2026-03-04 Springworks Therapeutics Inc Fluorinated phenylamine compounds and pharmaceutical compositions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ATE344791T1 (de) * 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
ES2229515T3 (es) * 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
JP2002534515A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1−複素環置換されたジアリールアミン
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2006083979A2 (en) 2005-02-02 2006-08-10 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
NZ567140A (en) * 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
GB0616214D0 (en) * 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2113500A1 (en) * 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JP5592253B2 (ja) * 2007-05-11 2014-09-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性疾患およびマイトジェン細胞外キナーゼ活性関連性疾患を治療するための置換フェニルアミノ−ベンゼン誘導体
US20080312307A1 (en) * 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
GB0801081D0 (en) * 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
JP7212956B2 (ja) * 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
ES2913213T3 (es) * 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
BR112020024039B1 (pt) * 2018-06-01 2023-12-26 Dow Global Technologies Llc Pró-catalisador heterogêneo, processo para polimerizar polímeros à base de etileno, e, processo de produção do pró-catalisador
CN113645964B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
WO2020106304A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Topical formulations
WO2020106305A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders

Similar Documents

Publication Publication Date Title
JP2022511127A5 (cg-RX-API-DMAC7.html)
MX2025011899A (es) Compuestos de pirido[4,3-d]pirimidina
PH12022550611A1 (en) Brd9 bifunctional degraders and their methods of use
KR102556744B1 (ko) B형 간염 항바이러스제
CN114765979A (zh) 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
EP3362443A1 (en) Compounds useful as immunomodulators
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JP6462045B2 (ja) スルフォラファンの単離及び精製
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
RU2009144538A (ru) Новые циклические пептидные соединения
JP2017513824A5 (cg-RX-API-DMAC7.html)
JP2022510586A5 (cg-RX-API-DMAC7.html)
JP2017518360A5 (cg-RX-API-DMAC7.html)
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
JP2022511730A5 (cg-RX-API-DMAC7.html)
WO2025049521A3 (en) Aryl ether analogs as inhibitors of the menin-mll interaction
CN111670189A (zh) 对rsv具有活性的环烷基取代的吡唑并嘧啶
CN104530127B (zh) 一种淫羊藿苷衍生物及其使用方法和用途
RU2017140078A (ru) Косметический способ и его терапевтическое применение для уменьшения объема жировой ткани
JP2013525290A5 (cg-RX-API-DMAC7.html)
CN104387358B (zh) 淫羊藿苷类化合物及其应用
EP2276464A2 (en) Combinations of antiviral agents and other compounds
CN104387288B (zh) 作为神经氨酸酶抑制剂的化合物及其在药物中的应用
RU2017102043A (ru) Новое соединение (ks513), выделенное из pseudolysimachion rotundum var. subintegrum, композиция, содержащая указанное соединение в качестве активного ингредиента, для предотващения или лечения аллергического заболевания, воспалительного заболевания, астмы или хронической обструктивной болезни легких и их применение
CN104447583B (zh) 含有环丁烷取代基的吡嗪类化合物及其组合物及用途